News

Nerviano Medical Sciences Srl (NMS Srl or NMS), a clinical stage biopharmaceutical leader in oncology innovation, announced its strategic plan to focus its research and development resources to progress its three biological targets, composed of PARP1, PARP7, and MPS1, and on its proprietary ADC platform composed of novel ADC payloads.  

Nerviano, Italy – 09 July 2025 – NMS Group S.p.A., the largest oncology-focused R&D organization in Italy, today announced the appointment of Mr. Victor Chu to its Board of Directors, effective immediately. Mr. Chu replaces Mr. Lincoln Pan, who has stepped down from the Board after a period of dedicated and impactful service.

NERVIANO, Italy and BOSTON, Mass., 28 April 2025 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage oncology company developing targeted therapies across DNA damage response and kinase pathways, today announced the initiation of two Phase 1 clinical trials evaluating its unique non-trapping, highly specific and brain penetrant PARP1 inhibitor NMS-293 in combination therapies for relapsed small cell lung cancer (SCLC) and BRCA wild-type ovarian cancer.  NMS-293 represents a third generation of PARP1 inhibitor using non-trapping as a way to combine with DNA-damaging therapies while preserving bone marrow safety.

NMS today announced a transaction with a group of investors, including NovaQuest Capital Management.

This transaction enables NMS to monetize a percentage of future Rozlytrek® (entrectinib) royalties, for an amount up to $21 million. Under the terms of the agreement, after a pre-set return on investment is reached by the purchasers, NMS retains all subsequent royalties tied to Rozlytrek® (entrectinib) global net sales.

We’re thrilled to share the presentation delivered by Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, Guest Speaker at the recent 8th Annual DDR Inhibitors Summit.

NMS and NMS Inc. are pleased to announce that the U.S. Food and Drug Administration (FDA) has granted approval to proceed with two clinical studies in the relapse setting for small cell lung cancer and BRCA wild-type ovarian cancer. These important milestones bring the company closer to advancing its PARP1-selective, non-trapping, brain penetrant inhibitor NMS- 293 and potentially transforming the treatment landscape for patients.

NERVIANO, Italy, January 7, 2025 – Nerviano Medical Sciences S.r.l. (NMS), a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that it has entered into a clinical trial supply agreement with Roche for provision of atezolizumab (Tecentriq®)1 to be combined with the Monopolar Spindle 1 (MPS1) inhibitor NMS-153, and cGAS/STING pathway activator, for the treatment of hepatocellular cancer patients.

Agreement reached with Merck KGaA to gain back the full rights of NMS-293
Available clinical data support NMS-293 as an ideal partner for combination with DNA-damaging agents like chemotherapies or ADC payloads: NMS will expand clinical development of NMS-293 beyond the ongoing Phase 2 study in combination with temozolomide in patients with relapsed glioblastoma.

NMS today announce the acquisition of atamparib, the first selective PARP7 inhibitor. This transaction highlights NMS’s commitment to solidify its leadership in PARP biology and expanding its pipeline with transformative cancer therapies designed to meet significant unmet medical needs.